Bristol-Myers Squibb - Crunchbase Company Profile & Funding

Q: Who invested in Bristol-Myers Squibb?

Bristol-Myers Squibb has 13 investors including RA Capital Management And OUP (Osage University Partners).

Q: How much funding has Bristol-Myers Squibb raised to date?

Bristol-Myers Squibb has raised obfuscated.

Overview

Bristol-Myers Squibb

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+5 more milestones

See more interactive data and historical milestones on desktop for the best experience

About Bristol-Myers Squibb

CB Rank

10163

Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.

Founded

obfuscation

Public

Post-IPO Debt

New York, New York, United States

101-250

www.bms.com

Biotechnology

Health Care

Medical

Pharmaceutical

Precision Medicine

Funding Rounds

Post-IPO Debt

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Post-IPO Debt

OBF

obfuscation

Key People

John damonti: Foundation President
Mita Maity: Research Scientist

Details

Legal Name

Bristol-Myers Squibb Company

Operating Status

Active

Number of Exits

obfuscation

Stock Symbol

NYSE:BMY

Company Type

For Profit

Founders

E. R. Squibb, John Ripley Myers, William McLaren Bristol

About the Company

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.

Investor Type

obfuscation

Investment Stage

obfuscation

Phone Number

(212)546-4000

Predictions & Insights

Growth Insight

See this Growth Insight

Bristol-Myers Squibb is

Lorem

to be growing

Top Contributing Factors

Financial Growth

Products & Services

Oncology Medicines

Pharmaceutical products developed to treat various types of cancer by targeting cancer cells and modulating immune responses.

Hematology Medicines

Drugs designed to treat blood disorders and diseases affecting the blood and bone marrow.

Research & Development

Bristol-Myers Squibb is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt
obfuscated obfuscation	Post-IPO Debt - Bristol-Myers Squibb	—	obfuscated obfuscation	—	Post-IPO Debt

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
RA Capital Management	—	Post-IPO Equity - Bristol-Myers Squibb	Peter Kolchinsky
RA Capital Management	—	Post-IPO Equity - Bristol-Myers Squibb	Peter Kolchinsky
RA Capital Management	—	Post-IPO Equity - Bristol-Myers Squibb	Peter Kolchinsky
RA Capital Management	—	Post-IPO Equity - Bristol-Myers Squibb	Peter Kolchinsky
RA Capital Management	—	Post-IPO Equity - Bristol-Myers Squibb	Peter Kolchinsky

Investments

Investment Breakdown

Diversity Investments

Number of Investments

107

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation

Investment Breakdown

Number of Investments

107

Number of Exits

obfuscation

Number of Acquisitions

See investment data for this company, with details on deal size, industry, stage, and more.

Announced Date	Organization Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation
obfuscated obfuscation	Precede Biosciences	—	Series B - Precede Biosciences	obfuscated obfuscation

Diversity Investments

Number of Diversity Investments

Announced Date	Organization Name	Diversity Spotlight	Funding Round	Money Raised
obfuscated obfuscation	Be Biopharma	Women Founded	Series C - Be Biopharma	obfuscated obfuscation
obfuscated obfuscation	Nuvig Therapeutics	Women Founded	Series B - Nuvig Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Be Biopharma	Women Founded	Venture Round - Be Biopharma	obfuscated obfuscation
obfuscated obfuscation	Roswell Park Cancer Institute	Women Led	Grant - Roswell Park Cancer Institute	obfuscated obfuscation
obfuscated obfuscation	Envisagenics	Hispanic / Latine Founded, Hispanic / Latine Led, Women Founded, Women Led	Series B - Envisagenics	obfuscated obfuscation
obfuscated obfuscation	Asher Bio	Women Founded, Women Led	Series C - Asher Bio	obfuscated obfuscation
obfuscated obfuscation	Q32 Bio	Women Founded	Post-IPO Equity - Q32 Bio	obfuscated obfuscation
obfuscated obfuscation	ROME Therapeutics	Women Founded, Women Led	Series B - ROME Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Mediar Therapeutics	Women Founded	Series A - Mediar Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Cajal Neuroscience	Women Founded	Series A - Cajal Neuroscience	obfuscated obfuscation